天津医药

天津医药 ›› 2022, Vol. 50 ›› Issue (3): 300-304.doi: 10.11958/20211402

• 临床研究 • 上一篇    下一篇

肿瘤坏死因子α诱导蛋白6在胃癌组织中的表达及其与预后的关系

戚利坤，王巍   

  1. 青海省肿瘤医院肿瘤外科（邮编810007）
  • 收稿日期:2021-06-15 修回日期:2021-12-03 出版日期:2022-03-15 发布日期:2022-03-15
  • 基金资助:
    青海省卫生计生委2018年医学科研课题（2018_wjzdx_12）

The expression level of tumor necrosis factor-α induced protein 6 (TNFαIP6) gastric cancer and its relationship with prognosis

QI Likun, WANG Wei   

  1. Department of Cancer Surgery, Qinghai Cancer Hospital, Xining 810007, China
  • Received:2021-06-15 Revised:2021-12-03 Published:2022-03-15 Online:2022-03-15

PDF (PC)

2611

摘要： 目的　探讨肿瘤坏死因子α诱导蛋白6（TNFαIP6）在胃癌中的表达及其与患者临床病理特征及预后的关系。方法　收集133例胃癌患者的临床病理资料及随访数据，通过免疫组化染色检测TNFαIP6在胃癌组织中的表达情况，分析TNFαIP6表达与胃癌临床病理特征的关系。绘制Kaplan-Meier生存曲线比较TNFαIP6高表达与低表达者的总生存率差异，采用Cox回归分析确定胃癌患者预后的影响因素。结果　133例患者中TNFαIP6高表达52例，低表达81例。低分化腺癌、Borrmann Ⅳ型、T3~T4期、M1期、淋巴结转移及血管侵犯患者TNFαIP6高表达的比例明显升高。生存分析显示，TNFαIP6高表达组5年总生存率较低表达组明显下降（56.5% vs. 82.9%，Log-rank χ2=12.404，P＜0.01)。Cox多因素分析证实，T3~T4期（HR=2.291，95%CI：1.028~5.103）、M1期（HR=3.628，95%CI：1.421~9.260）及TNFαIP6高表达（HR=2.742，95%CI：1.265~5.945）是胃癌患者预后的独立危险因素（均P＜0.05）。结论　TNFαIP6在胃癌组织中的高表达与肿瘤的侵袭性特征有关，是影响胃癌患者预后的一个独立标志物。

关键词: 胃肿瘤, 预后, 肿瘤坏死因子α诱导蛋白6, 临床病理特征

Abstract: Objective　To investigate the the expression level of tumor necrosis factor-α induced protein 6 (TNFαIP6)in gastric cancer and its correlation to clinicopathological features and survival outcome of gastric cancer patients. Methods　The clinicopathological and follow-up data of 133 gastric cancer patients who underwent surgical resection in our hospital were retrospectively collected. Immunohistochemical staining was used to evaluate the expression of TNFαIP6 in gastric cancer tissues, and the correlation between TNFαIP6 expression and clinicopathological characteristics of gastric cancer patients was analyzed. Kaplan-Meier survival curves were plotted to compare the survival difference between patients with high TNFαIP6 expression and patients with low TNFαIP6 expression. The independent prognostic value of TNFαIP6 expression for gastric cancer patients was determined by Cox multivariate regression analysis. Results　Among 133 patients, TNFαIP6 expression levels were high in 52 patients and low expression levels in 81 patients. The proportion of TNFαIP6 expression increased significantly in patients with poorly differentiated adenocarcinoma, Borrmann type Ⅳ, T3-T4 tumors, M1 stage and lymphatic vascular invasion. Kaplan-meier survival curve showed that the 5-year overall survival rate of patients with high TNFαIP6 expression was significantly lower than that of patients with low TNFαIP6 expression (56.5% vs. 82.9%, Log-rank χ2=12.404, P<0.01). Cox multivariate analysis confirmed that T3-T4 tumor (HR=2.291, 95%CI: 1.028-5.103), M1 stage (HR=3.628, 95%CI: 1.421-9.260) and high expression of TNFαIP6 (HR=2.742, 95%CI: 1.265-5.945) were independent risk factors affecting prognosis of gastric cancer patients. Conclusion　The high expression of TNFαIP6 in gastric cancer tissues is associated with the invasive characteristics of tumor, and which is an independent marker affecting the prognosis of gastric cancer patients.

Key words: stomach neoplasms, prognosis, tumor necrosis factor-α induced protein 6, clinicopathological features